Extended Data Fig. 2: Benefits of polypharmcotherapy to ameliorate mSTZ diabetes in mice.
From: Targeted pharmacological therapy restores β-cell function for diabetes remission
Effect of treatment with indicated compounds and doses on a, fasting plasma insulin levels at week 12 of treatment (mSTZ-vehicle, n = 12; oestrogen, n = 10; GLP-1, n = 11; GLP-1/oestrogen, n = 11; one-way ANOVA with Tukey post-hoc; F (3, 39) = 10.66) and b, body weight in the end of the study (no STZ-vehicle, n = 12; mSTZ-vehicle, n = 13; GLP-1, n = 11; oestrogen, n = 11; GLP-1/oestrogen, n = 11; PEG-insulin, n = 9; GLP-1/oestrogen and PEG-insulin, n = 10; unpaired two-sided t-test; t = 2.436, df = 17). (c, d) Comparison of PEG-insulin and GLP-1/oestrogen plus PEG-insulin co-treated mice. c, Blood glucose after intraperitoneal glucose (0.5 g/kg) at week 12 (no STZ-vehicle, n = 12; PEG-insulin, n = 9; GLP-1/oestrogen and PEG-insulin, n = 10; one-way ANOVA with Tukey post-hoc (F (2, 27) = 24.71)). d, Pancreatic insulin content in the end of the study (no STZ-vehicle, n = 4; PEG-insulin, n = 4; GLP-1/oestrogen and PEG-insulin, n = 4; unpaired two-sided t-test; t = 4.534, df = 6). All data are mean ± SEM.
